secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-09-29T12:45:26+00:00
Accession:  0001437749-26-031419
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin Biotech completes Part A enrollment in Phase 2/3 MIRACLE trial with 89 R/R AML subjects
--------------------------------------------------------------------------------

- Part A of the pivotal Phase 2/3 MIRACLE trial closed enrollment with 89 subjects enrolled and one additional subject in screening.
- Moleculin remains on track for a comprehensive Part A data readout in Q1 2027.
- The full Part A population is expected to be approximately 50/50 between 1L 7+3 and venetoclax-based regimens, versus a 70/30 split in the first 45 subjects.
- CEO Walter Klemp said the Q1 2027 readout will be deeper in data than the first interim n45 readout.
- The company continues to see no cardiotoxicity in blinded MIRACLE data; AnnAraC combines Annamycin with cytarabine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/0001437749-26-031419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/mbrx20260928_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer